Index by author
Oakes, T.R.
- Adult BrainOpen AccessStructural and Volumetric Brain MRI Findings in Mild Traumatic Brain InjuryJ.B. Patel, S.H. Wilson, T.R. Oakes, P. Santhanam and L.K. WeaverAmerican Journal of Neuroradiology January 2020, 41 (1) 92-99; DOI: https://doi.org/10.3174/ajnr.A6346
Ogawa, M.
- Adult BrainYou have accessVisualization of Nigrosome 1 from the Viewpoint of Anatomic StructureN. Arai, H. Kan, M. Ogawa, Y. Uchida, M. Takizawa, K. Omori, T. Miyati, H. Kasai, H. Kunitomo and Y. ShibamotoAmerican Journal of Neuroradiology January 2020, 41 (1) 86-91; DOI: https://doi.org/10.3174/ajnr.A6338
Omori, K.
- Adult BrainYou have accessVisualization of Nigrosome 1 from the Viewpoint of Anatomic StructureN. Arai, H. Kan, M. Ogawa, Y. Uchida, M. Takizawa, K. Omori, T. Miyati, H. Kasai, H. Kunitomo and Y. ShibamotoAmerican Journal of Neuroradiology January 2020, 41 (1) 86-91; DOI: https://doi.org/10.3174/ajnr.A6338
Ong, K.
- EDITOR'S CHOICESpine Imaging and Spine Image-Guided InterventionsYou have accessNumber Needed to Treat with Vertebral Augmentation to Save a LifeJ.A. Hirsch, R.V. Chandra, N.S. Carter, D. Beall, M. Frohbergh and K. OngAmerican Journal of Neuroradiology January 2020, 41 (1) 178-182; DOI: https://doi.org/10.3174/ajnr.A6367
The purpose of this study was to calculate the number needed to treat to save 1 life at 1 year and up to 5 years after vertebral augmentation. A 10-year sample of the 100% US Medicare data base was used to identify patients with vertebral compression fractures treated with nonsurgical management, balloon kyphoplasty, and vertebroplasty. The number needed to treat was calculated between augmentation and nonsurgical management groups from years 1–5 following a vertebral compression fracture diagnosis, using survival probabilities for each management approach. The adjusted number needed to treat to save 1 life for nonsurgical management versus kyphoplasty ranged from 14.8 at year 1 to 11.9 at year 5. The adjusted number needed to treat for nonsurgical management versus vertebroplasty ranged from 22.8 at year 1 to 23.8 at year 5. The authors conclude that the NNT analysis of more than 2 million patients with VCF reveals that only 15 patients need to be treated to save 1 life at 1 year. This has an obvious clinically significant impact and given that all augmentation clinical trials are underpowered to detect a mortality benefit, this large dataset analysis reveals that vertebral augmentation provides a significant mortality benefit over nonsurgical management with a low NNT.
Oran, I.
- NeurointerventionYou have accessReduced Activity of von Willebrand Factor after Flow-Diverting Stent Implantation for Intracranial Aneurysms: A Link to Acquired von Willebrand Disease?I. Oran, C. Cinar, H. Bozkaya, M. Parildar and S. DumanAmerican Journal of Neuroradiology January 2020, 41 (1) 140-146; DOI: https://doi.org/10.3174/ajnr.A6343